Daré Bioscience, Inc.’s Post

Thanks to American College of Obstetricians and Gynecologists (ACOG)'s Obstetrics & Gynecology journal for featuring our research in an editorial discussing Daré’s Phase 2b study efficacy results of topical Sildenafil Cream 3.6%, which is being developed for the treatment of female sexual arousal disorder (FSAD). Author JoAnn V. Pinkerton, MD, MSCP, from the Department of Obstetrics and Gynecology, University of Virginia Health, highlights the challenges of FSAD, and the potential of Sildenafil Cream to address an unmet need for women suffering from this complex condition. Read the full article (subscription required) here: https://bit.ly/3y4BTdH Also listen to the August episode of Obstetrics & Gynecology’s Green Room podcast featuring our published study results here: https://bit.ly/4f7ThyV

Our President and CEO, Sabrina Johnson, shared insights with Femtech World, alongside lawyers and investors in women’s health, on navigating challenges around raising money in the space, and the importance of partnering with credible advisors and aligned investors for a successful start-up journey.   Click the link to read the full article: https://bit.ly/4cH34KD

As summer rolls along, we’re taking a moment to spotlight our team at Daré, whose hard work and commitment drives our mission to transform women’s health. Our Laboratory Operations Manager Kayla Townsend shares below her passion for making a difference for women, and what inspires and motivates her every day. 

Did you know an estimated 45 million women in the U.S. are approaching or in menopause? In addition to a reduction in estrogen and other hormones, approximately 75% of menopausal women will also experience hot flashes and night sweats, collectively known as vasomotor symptoms (VMS), which often cause sleep disturbance, and vulvovaginal atrophy (VVA), the drying and thinning of vaginal tissues, which can cause a feeling of vaginal tightness during sex along with pain, burning, or soreness. The Menopause Society emphasizes that hormone therapy is the most effective treatment for VMS and the genitourinary syndrome of menopause – a chronic, progressive condition of the vulva, vagina, and lower urinary tract caused by a decrease in estrogen production – and that non-oral hormone delivery routes, such as transdermal or vaginal options, offer potential advantages by delivering the drug in a way that avoids the liver, increasing its effectiveness. Learn more about Daré’s efforts to address this unmet need by advancing an investigational intravaginal ring designed to deliver continuous hormone therapy to treat the vasomotor symptoms of menopause in a convenient monthly, non-oral format: https://lnkd.in/gsSsSNxx

Our President and CEO, Sabrina Johnson, recently spoke with Peter Ho, host of Brio360’s Value Drivers podcast on her approach to value creation. Listen to the full episode below at the link to hear Sabrina’s insights on the strategies and challenges behind advancing women’s health products, and how partnerships and creative, non-dilutive funding options can help deliver value to all stakeholders: https://lnkd.in/gwCnnZMA

Freedom can take many forms. As America celebrates the 248th year of its independence, we celebrate the freedom to pursue scientific advancement in the hopes of enabling women to live healthier, fuller lives, and a reminder of our responsibility to preserve this freedom, on behalf of women everywhere, from First Lady Michelle Obama. #IndependenceDay   

Female sexual arousal disorder (FSAD) is a life-altering condition that deserves more candid conversations and safe, accessible and well-tested treatment options. Thank you Healio and Contemporary OB/GYN for highlighting our Phase 2b study efficacy results for topical Sildenafil Cream 3.6%, being developed for the treatment of FSAD, which were recently published in Obstetrics & Gynecology, the official publication of the American College of Obstetricians and Gynecologists (ACOG). The Phase 2b clinical study showed that topical Sildenafil Cream improved outcomes among women with FSAD, most significantly in a subset of women both with and without concomitant decreased desire. In an exploratory post-hoc analysis of this group, topical Sildenafil Cream significantly increased sexual arousal sensation and reduced sexual distress, as well as improved desire and orgasm. Read more on the importance of these results and the potential of Sildenafil Cream as a first FDA-approved treatment for this significant unmet need: https://lnkd.in/evsTA7Rf; https://lnkd.in/eMfw-4fg Access Daré’s full published study manuscript here: https://bit.ly/3VRh3aA